ATC (Anatomical Therapeutic Chemical Classification)
CAS registry number (Chemical Abstracts Service)
Immunoglobulin G1-kappa auristatin E conjugate, anti-[Homo sapiensTNFRSF8 (tumor necrosis factor receptor superfamily member 8, KI-1, CD30)], chimeric monoclonal antibody conjugated to auristatin E; gamma1 heavy chain (1-446) [Mus musculusVH (IGHV1-84*02- (WHO )
- Brentuximabum Vedotinum (Latin)
- Brentuximab Vedotin (German)
- Brentuximab Védotine (French)
- Brentuximab Vedotina (Spanish)
- Brentuximab Vedotin (OS: USAN, BAN)
- Brentuximab Vedotin (Genetical Recombination) (OS: JAN)
- antibody-drug conjugate SGN-35 (IS)
- anti-CD30 ADC SGN-35 (IS)
- anti-CD30 antibody-drug conjugate SGN-35 (IS)
- cAC10-vcMMAE (IS)
- SGN-35 (IS)
- UNII-7XL5ISS668 (IS)
Seattle Genetics, Inc., United States; Takeda, Bosnia & Herzegowina; Takeda, Belgium; Takeda, Germany; Takeda, Spain; Takeda, Finland; Takeda, Hong Kong; Takeda, Croatia (Hrvatska); Takeda, Hungary; Takeda, Ireland; Takeda, Israel; Takeda, Italy; Takeda, Latvia; Takeda, Norway; Takeda, Poland; Takeda, Singapore; Takeda France, France; Takeda Pharma, Switzerland; Takeda Pharma, Denmark; Takeda Pharma, Sweden; Takeda Pharmaceutical, Japan; Takeda UK, United Kingdom
|BAN||British Approved Name|
|JAN||Japanese Accepted Name|
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.